Ligand and Genagon ink drug development agreement

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ JacobStudio)
(Image: Getty/ JacobStudio)

Related tags: Drug development, Drug development process, Preclinical contract research, preclinical, Preclinical services, Antibody, models, Immuno-oncology, Drug discovery

Ligand Pharmaceuticals enters an agreement with Genagon to provide access to its drug development platform capable of producing fully human antibodies.

Per the agreement, Genagon, a Swedish biotech focused on immuno-oncology development, will gain access to the Ligand’s full OmniAb platform for drug discovery which includes: OmniRat, OmniMouse, OmniFlic, and OmniChicken.

Genagon will use this access to develop antibody-based therapeutics for immuno-oncology targeting suppressive pathways on antigen presenting cells that the company has discovered.

John Higgins, CEO, Ligand said in a statement, “The OmniAb platform is innovative and it has proven itself to be a broadly-licensable technology that we will continue to leverage as we build our Shots-on-Goal business model.”

Higgins added that the platform is the only of its kind to offer access to “three species that produce fully-human antibodies.”

Ligand received an upfront payment and is eligible to receive development milestone payments and tiered royalties for each product incorporating an OmniAb-derived antibody. Genagon will be responsible for costs related to their programs.

Related news

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us


View more